We are driven by relationships and results. These select case studies highlight how we partner with our clients to deliver value and achieve their business objectives.
A midsize US pharmaceutical company was looking to understand protocols and the new product landscape for the acute lymphoblastic leukemia (ALL) market.
A small global biotech company had a single product in development for two separate indications with parallel Phase II studies in process.
A multinational biopharmaceutical company had an oncology agent in development expected to be a blockbuster. Launch timelines were accelerated when the product received Fast Track designation from the US FDA and orphan drug status in the EU.
A midsize global pharmaceutical company acquired a recently approved orphan drug therapy with the intent to launch in less than four months.
A small pharmaceutical company with three pipeline products at various stages of clinical development and limited cash reserves was preparing for acquisition.
A large, publicly held global pharmaceutical company was looking to establish a consistent approach to new product planning and brand management across all global affiliates.
A small, biotech start-up company with the goal of developing and marketing unique therapies for CNS disorders was preparing to launch its lead compound.
A small/emerging company had developed a proprietary formulation for a unique vaccine product and previously licensed the agent to a midsize partner.